Rivaroxaban (Xarelto)


Acute Coronary Syndrome (ee Coronary Artery Disease)

Clinical Efficacy

Peripheral Artery Disease (PAD) After Revascularization (see Peripheral Artery Disease)

FDA approved 2021 expanded peripheral artery disease (PAD) Indication for Xarelto® (rivaroxaban) plus aspirin to include patients after lower-extremity revascularization (LER) due to symptomatic PAD. News release. Janssen Pharmaceuticals, Inc. Accessed August 24, 2021. https://www.prnewswire.com/news-releases/fda-approves-expanded-peripheral-artery-disease-pad-indication-for-xarelto-rivaroxaban-plus-aspirin-to-include-patients-after-lower-extremity-revascularization-ler-due-to-symptomatic-pad-301361537.html.

Systemic Embolism Prevention in Non-Valvular Atrial Fibrillation (see Atrial Fibrillation)

Clinical Efficacy-General

Clinical Efficacy-Cost Effectiveness

Venous Thromboembolism (see Deep Venous Thrombosis and Acute Pulmonary Embolism)

Clinical Efficacy

Venous Thromboembolism Prophylaxis in Medical Patients (see Deep Venous Thrombosis and Acute Pulmonary Embolism)

Clinical Efficacy

Venous Thromboembolism Prophylaxis Post-Knee and Hip Replacement (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]] and Acute Pulmonary Embolism)

Clinical Efficacy


Mechanism of Action




PO Dosing

Effect on Anticoagulation Tests

Hepatic Dose Adjustment

Renal Dose Adjustment

Treatment of Venous Thromboembolism

Treatment of Non-Valvular Atrial Fibrillation

Venous Thromboembolism Prophylaxis

Dose Adjustment for Obesity (2016 International Society of Thrombosis and Hemostasis Recommendations) (J Thromb Haemost, 2016) [MEDLINE]

Drug Interactions

Pregnancy (see Pregnancy)

Conversion from/to Other Anticoagulants

Conversion From Rivaroxaban

Conversion to Rivaroxaban

Periprocedural/Perioperative Management of Rivaroxaban Anticoagulation

Recommendations for Periprocedural/Perioperative Management of Rivaroxaban (American College of Chest Physicians Clinical Practice Guideline for the Perioperative Management of Antithrombotic Therapy) (Chest, 2022) [MEDLINE]

Reversal of Rivaroxaban Anticoagulation

Activated Charcoal (see Activated Charcoal)

Andexanet Alfa (see Andexanet)

Hemodialysis (see Hemodialysis)

Prothrombin Complex Concentrate-4 Factor (Kcentra, Beriplex, Confidex) (see Prothrombin Complex Concentrate-4 Factor)

Recombinant Factor VIIa (see Factor VIIa)

Adverse Effects

Hemorrhagic Adverse Effects

Comparative Rates of Hemorrhage Between Coumadin and Novel Oral Anticoagulants

Types of Hemorrhage

Other Adverse Effects




Atrial Fibrillation

Venous Thromboembolism


Administration in Specific Clinical Subsets of Patients

Reversal of Anticoagulation

Adverse Effects